The percentage of the planned dose received, however, was superior in the dose-escalation group in cycle 2 (median 100·0% IQR 95·2–100·0 vs 75·0% 50·0–100·0). ...with a slightly better toxicity profile and comparable dose exposure in cycle 2, a higher percentage of patients initiated cycle 3 in the dose-escalation group, thus making ReDOS a positive trial. ...it is—as is often the case with clinical trials including patients in the refractory treatment setting—questionable whether the study results obtained in ReDOS are transferable to most patients treated under routine clinical conditions. ReDOS took almost 25 months to achieve its recruitment goal of 116 evaluable patients in 39 centres, an average of 1·4 patients per centre per year. ...an obviously small subset of all patients was included in the ReDOS study that might not represent the majority of patients treated with regorafenib.